Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable

Nooka, A., Costa, L., Gasparetto, C., Richardson, P., Siegel, D., Chari, A., Lentzsch, S., Jagannath, S., & Mikhael, J. (2022). Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. Clinical Lymphoma Myeloma and Leukemia, 22(7), e526–e531. https://doi.org/10.1016/j.clml.2022.01.014
Authors:
A. K. Nooka
L. J. Costa
C. J. Gasparetto
P. G. Richardson
D. S. Siegel
A. Chari
S. Jagannath
S. Lentzsch
J. Mikhael
Affiliated Authors:
S. Lentzsch
Columbia Affiliation:
Subjects:
Multiple Myeloma (MeSH)
Author Keywords:
relapsed and/or refractory myeloma
sine
selective inhibitor of nuclear export
selinexor
xpo1 inhibitor
relapsed and
or refractory myeloma
elink
Publication Type:
Article
Unique ID:
10.1016/j.clml.2022.01.014
PMID:
35361554
DOI:
10.1016/j.clml.2022.01.014
Journal:
Clinical Lymphoma, Myeloma and Leukemia
Publication Date:
Data Source:
Web of Science
Source Link:
View Web of Science Record
View PubMed Record

Record Created: